HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

3rd Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 24-26, 2022 | Orlando, Florida, USA

ce-approved
GAB 2022

Combination in patients with Alcohol Use Disorder A 12 Week, Randomized, Placebo Controlled Pilot Study

Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2022 - Ariel Wilson
University of Virginia, United States
Title : Combination in patients with Alcohol Use Disorder A 12 Week, Randomized, Placebo Controlled Pilot Study

Abstract:

Alcohol use disorder has proven consistently difficult to treat with currently approved medications showing a small effect size.1 Topiramate (TPM) has shown promising results as a potential treatment of alcohol use disorder through its anti-craving effects, but its use is limited by cognitive side effects. This cognitive impairment has been attributed to increased oxidative stress in neurons due to a lack of glutathione, which requires cysteine and the cysteine-glutamate antiporter (xCT). 6 N-acetylcysteine (NAC) has the potential to reduce the cognitive impairments caused by TPM, as it does not require the use of the xCT antiporter to enter neurons and can therefore replete glutamate concentrations. NAC also has the potential to work synergistically with TPM thereby reducing alcohol craving and drinking more efficaciously than either drug alone. The current study was a randomized, double-blind pilot study designed to evaluate the effectiveness and side effect profile of the combination of TPM + NAC versus TPM + placebo. We found that both treatment groups showed a significant reduction in alcohol use at the end of the study compared to baseline. However, there was no significant difference between groups in their reduction in alcohol use. Furthermore, there was no significant difference between groups for cognitive side effects. This study supports the current evidence that TPM is an effective medication for alcohol use disorder, and that NAC may not provide additional benefit in the reduction of alcohol use or cognitive side effects.

What will audience learn from your presentation?

  • Topiramate is an effective medication for reducing alcohol consumption in patients with Alcohol Use Disorder.
  • Not all patients who are treated with topirmate for Alcohol Use Disorder suffer from cognitive side effects.
  • N-acetylcysteine (NAC) does not appear to mitigate potential cognitive side effects from topiramate nor provide additional therapeutic benefit.

Biography:

Ariel Wilson graduated from the University of California San Diego in 2009 with a Bachelor of Arts in Psychology. She attended the University of Virginia School of Medicine in 2018 and will pursue a residency in psychiatry following her graduation from medical school in May 2022.

Watsapp